Global Overview of the Market for Spectroscopy Devices for Monitoring Patient Glucose Levels – ResearchAndMarkets.com

The “Spectroscopy Devices for Monitoring Patient Glucose Levels” report has been added to ResearchAndMarkets.com’s offering.

Noninvasive monitors that can measure analyte levels accurately and reliably have the capability to improve disease control and patient wellbeing.

By integrating the sensing element, electronics, and a power source in a single package, noninvasive monitors are creating new options for caregivers and their patients.

Signal processing improvements – including improved signal-to-noise ratios and interference filtering – will continue to be critical to the commercialization prospects of noninvasive monitors.

Spectroscopic Devices Glucose Measurement – What You Will Learn

  • What are the noninvasive sensing and monitoring technologies that are being pursued, who are the players behind them, and what is their development status?
  • What are the key noninvasive spectroscopic monitoring device design issues and evolving market factors?
  • What is the global market potential for optical monitors today? What will it be in 2024?
  • What will be the likely impact of the availability of commercial noninvasive sensing technology and devices on disease management markets?
  • Who are the market participants in the noninvasive monitoring sector? What are their technologies, product development activities and business strategies?
  • What will be the impact of economic, technology, and regulatory factors on the commercial potential of spectroscopic device patient monitors?

Key Topics Covered:

  • Executive Summary
  • Glucose Sensing Market Overview
  • Monitoring Glucose Levels
  • Key Factors in Patient Compliance
  • Market Drivers
  • Industry Alignment and Competitive Landscape
  • Noninvasive Glucose Measurement Design Factors
  • Measuring Glucose in Interstitial Fluid
  • Patient/User Interface
  • Reliability
  • Data Collection & Reporting
  • Commercial Track NGM Technologies
  • Spectroscopy
  • Raman
  • Infrared
  • Reverse Iontophoresis
  • Continuous Glucose Monitoring
  • Near-term Noninvasive Glucose Measurement Device Analysis
  • Optical Data Collection
  • Direct Analyte Measurement
  • Multimode Sensing
  • Forecasts
  • Important Private Research Programs
  • Asia
  • Soompo Japan Research Institute
  • Toyama Medical And Pharmaceutical University (Japan)
  • North America
  • Juvenile Diabetes Research Foundation (USA)
  • Juvenile Diabetes Research Foundation (USA)
  • Europe
  • Medical University of Graz (Austria)
  • Medical Research Foundation (The Netherlands)
  • Commercialization Factors
  • Calibration Frequency
  • Accuracy & Precision
  • Sensitivity
  • Sensor Technology & Signal Processing Advances
  • Market Factors
  • Regulations
  • FDA
  • EMEA
  • Asia (Japan)
  • Clinical Trials
  • Company Profiles

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”